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Introduction
Inhaled dry powders are the preferred route of delivery for
many respiratory medicines. Toxicology studies are routi-
nely carried out on inhaled dry powders whereas early
pre-clinical in vivo efficacy studies often use aqueous for-
mulations. Ideally evaluation of in- vivo efficacy, duration
of action and DMPK of novel compounds, delivered as dry
powders, should be carried out at an earlier stage in the
drug development process. This would allow direct com-
parisons to be made with toxicology data to establish a
therapeutic index and enable a more relevant prediction of
clinical efficacy.
Methods
We have evaluated the efficacy of Fluticasone Propionate
delivered as a dry powder, using an Aerosolised Dust Gen-
eration (ADG) tower and a mini-Wrights Dust Feeder II
(WDF), in a rat model of LPS induced pulmonary neutro-
philia. To more accurately control the doses the animals
received we used an Aerosol Particle Sizer (APS) to mea-
sure, in real time, the airstream compound concentration.
Using this inhaled delivery system allows a more physiolo-
gically relevant delivery and distribution to the lungs. The
ADG tower and WDF were identical to those used in
house for standard safety assessment studies with novel
respiratory target molecules.
Results
We have shown a dose-related inhibition of LPS-induced
pulmonary neutrophilia following inhaled delivery of a
range of doses of Fluticasone Priopionate. Analysis of lung
and plasma concentrations of Fluticasone, plus measure-
ment of airstream compound concentration enabled more
accurate dosimetry calculations.
Conclusion
Use of this standard inhaled dry powder delivery techni-
que may more closely link early pre-clinical efficacy and
toxicology studies and allow direct comparisons to be
made to establish a therapeutic index, and therefore
potentially a more relevant prediction of clinical efficacy.
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